Masimo Co. (NASDAQ:MASI) Receives $163.67 Average Price Target from Analysts

Masimo Co. (NASDAQ:MASI) has been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $163.67.

A number of equities analysts have issued reports on MASI shares. Piper Sandler increased their target price on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. BTIG Research upped their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Wells Fargo & Company raised their price target on shares of Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Finally, Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective on the stock in a research report on Wednesday, November 6th.

Masimo Stock Up 0.6 %

Shares of Masimo stock opened at $161.07 on Tuesday. The company has a market capitalization of $8.62 billion, a P/E ratio of 111.08 and a beta of 0.97. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The business has a 50-day moving average of $138.18 and a two-hundred day moving average of $126.95. Masimo has a 1 year low of $91.25 and a 1 year high of $173.90.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.63 EPS. As a group, equities analysts predict that Masimo will post 4.04 EPS for the current year.

Hedge Funds Weigh In On Masimo

Several hedge funds and other institutional investors have recently made changes to their positions in MASI. NBC Securities Inc. lifted its stake in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares during the last quarter. GAMMA Investing LLC grew its holdings in Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares during the last quarter. HHM Wealth Advisors LLC lifted its position in shares of Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its stake in shares of Masimo by 5,730.0% during the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 573 shares during the period. 85.96% of the stock is owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.